

Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholding

Paris, France and Camberley, UK – 13 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 12 November 2020, Jean-Pierre Crinelli, a Non-Executive Director of the Company, purchased 1,541 ordinary shares of €1/15 each in the Company at a price of €9.70 per share.

Following the purchase, Mr Crinelli is interested in 30,773 ordinary shares representing 0.04% of the issued share capital. This amount includes 8,000 ordinary shares purchased by Mr Crinelli at a price of €1.274 per share on 20 March 2020 which inadvertently was not disclosed by Mr Crinelli at the time.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

| | | | | | | |
|-------|---|---|-------|--------|-------|-------|
| 1. | Details of the person discharging managerial responsibilities / person closely associated | | | | | |
| a) | Name | Jean-Pierre Crinelli – Non-Executive Director | | | | |
| 2. | Reason for the Notification | | | | | |
| a) | Position/status | See 1(a) - classified as a PDMR of the Company | | | | |
| b) | Initial notification/ Amendment | Initial Notification | | | | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | | |
| a) | Name | Novacyt S.A. | | | | |
| b) | LEI | 213800BWAC2BF295EG28 | | | | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | | |
| a) | Description of the Financial instrument, type of instrument | ordinary shares of €1/15 each | | | | |
| | Identification code | FR0010397232 | | | | |
| b) | Nature of the transaction | Acquisition of Ordinary Shares | | | | |
| c) | Price(s) and volume(s) | <table border="1"> <tr> <td>Price</td><td>Volume</td></tr> <tr> <td>€9.70</td><td>1,541</td></tr> </table> | Price | Volume | €9.70 | 1,541 |
| Price | Volume | | | | | |
| €9.70 | 1,541 | | | | | |
| d) | Aggregated information: · Aggregated volume · Price | <p>N/A Single transaction as above</p> <table border="1"> <tr> <td>Price</td><td>Volume</td></tr> <tr> <td>€9,70</td><td>1,541</td></tr> </table> | Price | Volume | €9,70 | 1,541 |
| Price | Volume | | | | | |
| €9,70 | 1,541 | | | | | |
| e) | Date of the transaction | | | | | |

| | | |
|----|--------------------------|-----------------------|
| | | 12 November 2020 |
| f) | Place of the transaction | Paris Euronext Growth |

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

| 1. | Details of the person discharging managerial responsibilities / person closely associated | | | | | |
|--------|---|--|-------|--------|--------|-------|
| a) | Name | Jean-Pierre Crinelli – Non-Executive Director | | | | |
| 2. | Reason for the Notification | | | | | |
| a) | Position/status | See 1(a) - classified as a PDMR of the Company | | | | |
| b) | Initial notification/ Amendment | Initial Notification | | | | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | | |
| a) | Name | Novacyt S.A. | | | | |
| b) | LEI | 213800BWAC2BF295EG28 | | | | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | | |
| a) | Description of the Financial instrument, type of instrument | ordinary shares of €1/15 each | | | | |
| | Identification code | FR0010397232 | | | | |
| b) | Nature of the transaction | Acquisition of Ordinary Shares | | | | |
| c) | Price(s) and volume(s) | <table border="1"> <thead> <tr> <th>Price</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>€1.274</td> <td>8,000</td> </tr> </tbody> </table> | Price | Volume | €1.274 | 8,000 |
| Price | Volume | | | | | |
| €1.274 | 8,000 | | | | | |
| d) | Aggregated information: · Aggregated volume · Price | <p>N/A Single transaction as above</p> <table border="1"> <thead> <tr> <th>Price</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>€1.274</td> <td>8,000</td> </tr> </tbody> </table> | Price | Volume | €1.274 | 8,000 |
| Price | Volume | | | | | |
| €1.274 | 8,000 | | | | | |
| e) | Date of the transaction | 20 March 2020 | | | | |
| f) | Place of the transaction | Paris Euronext Growth | | | | |

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black
+44 (0)20 7260 1000

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of *in vitro* and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com